165 related articles for article (PubMed ID: 16908338)
1. Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit.
Marschall-Kehrel D; Roberts RG; Brubaker L
Urology; 2006 Aug; 68(2 Suppl):29-37. PubMed ID: 16908338
[TBL] [Abstract][Full Text] [Related]
2. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
3. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
4. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.
Coyne KS; Sexton CC; Irwin DE; Kopp ZS; Kelleher CJ; Milsom I
BJU Int; 2008 Jun; 101(11):1388-95. PubMed ID: 18454794
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.
Brubaker L; Chapple C; Coyne KS; Kopp Z
Urology; 2006 Aug; 68(2 Suppl):3-8. PubMed ID: 16908335
[TBL] [Abstract][Full Text] [Related]
6. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
7. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire.
Piault E; Evans CJ; Espindle D; Kopp Z; Brubaker L; Abrams P
Neurourol Urodyn; 2008; 27(3):179-90. PubMed ID: 17565727
[TBL] [Abstract][Full Text] [Related]
9. Symptom severity and patient perceptions in overactive bladder: how are they related?
Homma Y; Gotoh M
BJU Int; 2009 Oct; 104(7):968-72. PubMed ID: 19338560
[TBL] [Abstract][Full Text] [Related]
10. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
[TBL] [Abstract][Full Text] [Related]
11. Overactive bladder in women: symptom impact and treatment expectations.
MacDiarmid S; Rosenberg M
Curr Med Res Opin; 2005 Sep; 21(9):1413-21. PubMed ID: 16197660
[TBL] [Abstract][Full Text] [Related]
12. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
Choo MS; Doo CK; Lee KS
Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
[TBL] [Abstract][Full Text] [Related]
13. Medical care perceptions in elderly patients with musculoskeletal complaints.
Hershkovitz A; Rothschild BM; Rose JH; Hornick T; O'Toole EE
Isr Med Assoc J; 2001 Nov; 3(11):822-7. PubMed ID: 11729577
[TBL] [Abstract][Full Text] [Related]
14. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
Bolge SC; McDonnell DD; Chen A; Wan GJ
Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
[TBL] [Abstract][Full Text] [Related]
15. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients.
Michel MC; Oelke M; Goepel M; Beck E; Burkart M
Neurourol Urodyn; 2007; 26(2):190-5. PubMed ID: 17096320
[TBL] [Abstract][Full Text] [Related]
16. Impact of overactive bladder on women in the United States: results of a national survey.
Dmochowski RR; Newman DK
Curr Med Res Opin; 2007 Jan; 23(1):65-76. PubMed ID: 17257467
[TBL] [Abstract][Full Text] [Related]
17. Overactive bladder significantly affects quality of life.
Abrams P; Kelleher CJ; Kerr LA; Rogers RG
Am J Manag Care; 2000 Jul; 6(11 Suppl):S580-90. PubMed ID: 11183901
[TBL] [Abstract][Full Text] [Related]
18. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.
Toglia MR; Serels SR; Laramée C; Karram MM; Nandy IM; Andoh M; Seifeldin R; Forero-Schwanhaeuser S
Postgrad Med; 2009 Sep; 121(5):151-8. PubMed ID: 19820284
[TBL] [Abstract][Full Text] [Related]
19. Great expectations: really the novel predictor of outcome after spinal surgery?
Mannion AF; Junge A; Elfering A; Dvorak J; Porchet F; Grob D
Spine (Phila Pa 1976); 2009 Jul; 34(15):1590-9. PubMed ID: 19521272
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts.
Coyne KS; Tubaro A; Brubaker L; Bavendam T
Urology; 2006 Aug; 68(2 Suppl):9-16. PubMed ID: 16908336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
